ClinicalTrials.gg
CompletedNCT00918255Updated May 9, 2011Results posted

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

A Phase 2 interventional study of adalimumab and Placebo in Hidradenitis Suppurativa, sponsored by Abbott. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-09.

Sponsored by Abbott · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
44th of 139
154 · median 45
Started
2009
the only one that year
Phase 2
61 of 161
11 open now
Registered
7th of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 44th largest by enrollment of the 139 interventional ones that give a count, is the only one that started in 2009, is one of 61 in phase 2, and was the 7th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.

Read the detailed description

This Phase 2 randomized, double-blind, placebo-controlled multicenter study consists of 2 treatment periods: a 16-week double-blind, placebo-controlled period (Period 1: Weeks 0 through the end of Week 15) followed by a 36-week open-label period (Period 2: Weeks 16 through 52). Participants are randomized in a 1:1:1 ratio based on Hurley Stage as stratification factor to receive adalimumab 40 mg every week (qwk), adalimumab 40 mg every other week (eow), or matching placebo during Period 1. During Period 2, participants receive open-label adalimumab 40 mg eow with the option to escalate to 40 mg weekly dosing at Week 28 or Week 31 if the participant has a Physician's Global Assessment of moderate disease or worse (score of greater than or equal to 3). The primary objective of the study is to determine the clinical efficacy and safety of participants with moderate to severe chronic hidradenitis suppurativa (HS) after 16 weeks of treatment. The secondary objective is to evaluate the maintenance of efficacy and continued safety of adalimumab for an additional 36 weeks of treatment. (Note: Hurley Stage is a classification system for skin involvement that is largely based on the presence and extent of abscess formation accompanied by scarring and sinus tracts. Hurley Stages are I [abscess formation without scarring and sinus tracts], II [widely separated recurrent abscesses with scarring and sinus tracts], and III [multiple interconnected abscesses and sinus tracts across entire area]. Randomization in this study was performed using stratification by Hurley Stage [III versus (I or II).) At the present time, Period 1 double-blind data only is provided; additional information will be provided when analysis of open-label Period 2 is completed.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • Adalimumab
  • Nodule
  • Abscess
  • Fistula
  • Physicians Global Assessment
  • Hurley Stage
  • Sartorius Scale
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with stable, moderate to severe hidradenitis suppurativa
  • Negative Chest X-ray and PPD test at Screening. If participant has had a past ulcerative reaction to PPD placement and/or chest X-ray consistent with prior tuberculosis exposure, the participant must initiate, or have documented completion of, a course of anti-tuberculosis therapy.
  • Ability to administer subcutaneous injections
  • General good health otherwise

Exclusion criteria

Exclusion Criteria:

  • Prior anti-TNF therapy
  • Unstable antibiotic therapy for HS
  • Required medication washouts for other HS treatments
  • Prior exposure to Tysabri® (natalizumab);
  • Recent infection requiring treatment
  • Significant medical events or conditions that may put patients at risk for participation
  • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;
  • History of cancer, except successfully treated skin cancer
  • Recent history of drug or alcohol abuse
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Adalimumab 40 mg qwk

    Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.

    Biological: adalimumab

  • Experimental
    Adalimumab 40 mg eow

    Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.

    Biological: adalimumab

  • Placebo comparator
    Placebo

    Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.

    Drug: Placebo

Interventions

  • Biologicaladalimumab

    Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters

    Also known as: ABT-D2E7, Humira

  • DrugPlacebo

    Subcutaneous injection using prefilled syringe containing 0.8 milliliters

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Response at Week 16

    Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 16

    Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving Clinical Response at Week 2

    Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

    Time frame: Baseline, Week 2

  3. Percentage of Participants Achieving Clinical Response at Week 4

    Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

    Time frame: Baseline, Week 4

  4. Percentage of Participants Achieving Clinical Response at Week 8

    Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

    Time frame: Baseline, Week 8

  5. Percentage of Participants Achieving Clinical Response at Week 12

    Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

    Time frame: Baseline, Week 12

  6. Change From Baseline in Modified Sartorius Scale at Week 16

    The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.

    Time frame: Baseline, Week 16

  7. Change From Baseline in Modified Sartorius Scale at Week 52

    The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.

    Time frame: Baseline, Week 52

  8. Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 52

    Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.

    Time frame: Baseline, Week 52

07

Results

Posted May 9, 2011

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Started515251
Completed455246
Not completed605
Withdrew: Adverse event100
Withdrew: Withdrawal by subject102
Withdrew: Lack of efficacy100
Withdrew: Lost to follow-up102
Withdrew: Exceeded allowed number of interventions001
Withdrew: Non-compliance100
Withdrew: Investigator discretion100

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Response at Week 16

Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 16
percentage of participantsAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Percentage of Participants Achieving Clinical Response at Week 1617.69.63.9
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.022 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.025Analyzed using CMH test stratified by Hurley Stage.
  • Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.252Analyzed using CMH test stratified by Hurley Stage.
SecondaryPercent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 16

Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 16
percent changeAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 16-50.66 ± 11.364-30.43 ± 11.452-13.66 ± 11.452
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · ANCOVA · p = 0.062 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · ANCOVA · p = 0.019Analyzed using ANCOVA adjusting for Baseline Hurley Stage (I/II vs III).
  • Adalimumab 40 mg Eow DB vs Placebo DB · ANCOVA · p = 0.286Analyzed using ANCOVA adjusting for Baseline Hurley Stage (I/II vs III).
SecondaryPercentage of Participants Achieving Clinical Response at Week 2

Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

Time frame:
Baseline, Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 2
percentage of participantsAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Percentage of Participants Achieving Clinical Response at Week 22.09.62.0
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 1.000 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 1.000Analyzed using CMH test stratified by Hurley Stage.
  • Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.097Analyzed using CMH test stratified by Hurley Stage.
SecondaryPercentage of Participants Achieving Clinical Response at Week 4

Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

Time frame:
Baseline, Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 4
percentage of participantsAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Percentage of Participants Achieving Clinical Response at Week 411.85.82.0
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.044 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.051Analyzed using CMH test stratified by Hurley Stage.
  • Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.320Analyzed using CMH test stratified by Hurley Stage.
SecondaryPercentage of Participants Achieving Clinical Response at Week 8

Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

Time frame:
Baseline, Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 8
percentage of participantsAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Percentage of Participants Achieving Clinical Response at Week 87.85.87.8
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 1.000 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 1.000Analyzed using CMH test stratified by Hurley Stage.
  • Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.673Analyzed using CMH test stratified by Hurley Stage.
SecondaryPercentage of Participants Achieving Clinical Response at Week 12

Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 12
percentage of participantsAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Percentage of Participants Achieving Clinical Response at Week 1221.67.75.9
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.012 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.020Analyzed using CMH test stratified by Hurley Stage.
  • Adalimumab 40 mg Eow DB vs Placebo DB · Cochran-Mantel-Haenszel · p = 0.721Analyzed using CMH test stratified by Hurley Stage.
SecondaryChange From Baseline in Modified Sartorius Scale at Week 16

The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.

Time frame:
Baseline, Week 16
Reported as:
Median · scores on a scale
Change From Baseline in Modified Sartorius Scale at Week 16
scores on a scaleAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
Change From Baseline in Modified Sartorius Scale at Week 16-30.0 ± 53.82-16.0 ± 82.54-7.5 ± 47.78
Statistical analysis
  • Adalimumab 40 mg Qwk DB vs Adalimumab 40 mg Eow DB vs Placebo DB · Van Elteren test · p = 0.045 (When this initial overall comparison of the 3 treatment groups was significant, pairwise comparisons of each adalimumab dose group versus placebo were performed.)
  • Adalimumab 40 mg Qwk DB vs Placebo DB · Van Elteren test · p = 0.014Analyzed using Van Elteren test stratified by Hurley Stage.
  • Adalimumab 40 mg Eow DB vs Placebo DB · Van Elteren test · p = 0.169Analyzed using Van Elteren test stratified by Hurley Stage.
SecondaryChange From Baseline in Modified Sartorius Scale at Week 52

The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.

Time frame:
Baseline, Week 52
Reported as:
scores on a scale

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 52

Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.

Time frame:
Baseline, Week 52
Reported as:
percent change

Results for this outcome have not been posted.

Adverse events

Collected over For the 3 treatment groups in Period 1 (Adalimumab 40 mg Qwk, Adalimumab 40 mg Eow, and Placebo): Week 0 up to Week 16. For Open-label adalimumab (Period 2): Week 16 through Week 52 plus 70 days after the last dose.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg Qwk DB—4/51 (7.8%)36/51 (70.6%)
Adalimumab 40 mg Eow DB—3/52 (5.8%)33/52 (63.5%)
Placebo DB—2/51 (3.9%)30/51 (58.8%)
Most frequent serious events
Most frequent serious events
EventAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
AnaemiaBlood and lymphatic system disorders1/510/520/51
Small intestinal obstructionGastrointestinal disorders0/510/521/51
Non-cardiac chest painGeneral disorders1/510/520/51
Escherichia infectionInfections and infestations1/510/520/51
Genital infection bacterialInfections and infestations1/510/520/51
Vocal cord neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/520/51
Suicide attemptPsychiatric disorders0/510/521/51
Pilonidal cystInfections and infestations0/511/520/51
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/511/520/51
HidradenitisSkin and subcutaneous tissue disorders0/511/520/51
Most frequent other events
Showing 10 of 36
Most frequent other events
EventAdalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DB
HeadacheNervous system disorders8/517/522/51
NasopharyngitisInfections and infestations6/517/526/51
HidradenitisSkin and subcutaneous tissue disorders4/516/526/51
NauseaGastrointestinal disorders4/512/521/51
Upper respiratory tract infectionInfections and infestations4/514/522/51
Gastrooesophageal reflux diseaseGastrointestinal disorders3/510/520/51
VomitingGastrointestinal disorders1/512/523/51
FatigueGeneral disorders3/512/522/51
FolliculitisInfections and infestations0/510/523/51
ArthralgiaMusculoskeletal and connective tissue disorders3/510/521/51

Baseline characteristics

Age Continuous
Age Continuous(years)Adalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DBTotal
Mean35.1 ± 10.6936.1 ± 12.5037.8 ± 12.1036.3 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DBTotal
Female363836110
Male15141544
Region of Enrollment
Region of Enrollment(participants)Adalimumab 40 mg Qwk DBAdalimumab 40 mg Eow DBPlacebo DBTotal
United States413936116
Europe10131538
08

Study locations

26 sites
  • Site Ref # / Investigator 19062
    Birmingham, Alabama 35205, United States
  • Site Ref # / Investigator 18201
    Bakerfield, California 93309, United States
  • Site Ref # / Investigator 18467
    Los Angeles, California 90045, United States
  • Site Ref # / Investigator 18207
    San Diego, California 92103, United States
  • Site Ref # / Investigator 18204
    Miami, Florida 33136, United States
  • Site Ref # / Investigator 18209
    Atlanta, Georgia 30327, United States
  • Site Ref # / Investigator 18202
    Skokie, Illinois 60077, United States
  • Site Ref # / Investigator 18211
    Evansville, Indiana 47714, United States
  • Site Ref # / Investigator 18203
    Boston, Massachusetts 02111, United States
  • Site Ref # / Investigator 18210
    Boston, Massachusetts 02114, United States
  • Site Ref # / Investigator 18461
    St Louis, Missouri 63104, United States
  • Site Ref # / Investigator 18466
    Omaha, Nebraska 68144, United States
  • Site Ref # / Investigator 19141
    New York, New York 10016, United States
  • Site Ref # / Investigator 18208
    New York, New York 10019, United States
  • Site Ref # / Investigator 19001
    Winston-Salem, North Carolina 27103, United States
  • Site Ref # / Investigator 18981
    Hershey, Pennsylvania 17033, United States
  • Site Ref # / Investigator 18464
    Philadelphia, Pennsylvania 19104, United States
  • Site Ref # / Investigator 19061
    Dallas, Texas 75246-1613, United States
  • Site Ref # / Investigator 18463
    San Antonio, Texas 78258, United States
  • Site Ref # / Investigator 18206
    Norfolk, Virginia 23507, United States
  • Site Ref # / Investigator 18683
    Copenhagen NV, 2400, Denmark
  • Site Ref # / Investigator 18684
    Roskilde, 4000, Denmark
  • Site Ref # / Investigator 18471
    Dessau, 06847, Germany
  • Site Ref # / Investigator 18469
    Kiel, 24105, Germany
  • Site Ref # / Investigator 18470
    Amsterdam, 1105 AZ, Netherlands
  • Site Ref # / Investigator 18468
    Rotterdam, 3015 CA, Netherlands
09

References and documents

Publications

  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
  • Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J. 2016 Mar 16;22(3):13030/qt38x5922j. PubMed 27136622 ↗
  • Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012 Dec 18;157(12):846-55. doi: 10.7326/0003-4819-157-12-201212180-00004. PubMed 23247938 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Mar 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2009
First posted
Jun 11, 2009
Start
Apr 2009
Primary completionActual
Mar 2010
CompletionActual
Nov 2010
Results first posted
May 9, 2011
Last update
May 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00918255
Lead sponsor
Abbott
First posted
Jun 11, 2009
Start date
Apr 2009
Primary completion
Mar 2010
Completion
Nov 2010
Results posted
May 9, 2011
Last update
May 9, 2011

Study contacts

Martin Okun, MD, PhD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion